Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Selinexor
Related studies linked through entity extraction aliases.
Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1
Selinexor Combination Ph 1 Study
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
- Status
- RECRUITING
- Phase
- PHASE2
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
- Status
- TERMINATED
- Phase
- PHASE2